Navigating Biopharma Policy: 2025 Changes and a Look Ahead

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael, Senior Business & Finance Editor

IndustryLife Sciences & Healthcare

Biopharma firms are grappling with a turbulent and complex policy landscape. The threat of 100% tariffs on imported branded drugs have fundamentally altered business strategy for firms, spurring dealmaking with the federal government in exchange for tariff relief. Heightened policy uncertainty is forcing manufacturers to reevaluate pricing and go-to-market strategies, with a severe expected revenue impact.

AlphaSense recently hosted a webinar with Dr. Robert Popovian, Chief Science Policy Officer at the Global Health Living Foundation to discuss these issues and more. This report leverages key insights from Dr. Popovian and those available in AlphaSense to explore the key policy shifts shaping the biopharma ecosystem.

About the Authors

Sara Mallatt, Director of Healthcare Research
Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
Sean Carmichael, Senior Business & Finance Editor
Sean is a Senior Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.